Genmab Stock - Minor capital increase after employee warrant exercise
17.06.2026 - 18:11:08 | ad-hoc-news.de
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 18:10 CET. Details in the imprint.
Genmab (DK0010272202) has reported a small capital increase following the exercise of employee warrants. According to an IR release dated 06/16/2026, the biotech group issued 185 new shares, resulting in only negligible dilution for existing shareholders.
All news and key data on Genmab stock
Background pieces, regulatory filings and current quote information help investors follow Genmab's antibody-focused growth story.
Details of the capital increase
The new shares were issued as a result of employee warrant exercises under Genmab's long-term incentive program, with 185 shares subscribed in total according to the company statement.
The capital increase is described as "minor," and the resulting dilution for existing shareholders is effectively negligible given Genmab's multi-hundred-million-share base.
Wednesday focus on operations and capital structure
From an operational perspective, the warrant exercise fits into Genmab's broader approach of using equity-based compensation to align employees with the long-term antibody portfolio strategy.
The company recently published updated Articles of Association dated 06/16/2026, which reflect the adjusted share capital and confirm its framework for future capital actions and incentive schemes.
How the company makes money
Genmab generates most of its revenue from antibody-based cancer therapies, particularly royalties and milestone payments from products such as Darzalex (daratumumab), Tivdak and Epkinly that are developed and commercialized with partners.
Where the stock trades today
Genmab shares (DK0010272202) trade on Nasdaq Copenhagen under the ticker GMAB at DKK 1,556.00 as of 06/17/2026, 18:10 CET.
Key facts on Genmab stock
- Company: Genmab A/S
- ISIN: DK0010272202
- WKN: 117534
- Ticker: GMAB
- Venue: Nasdaq Copenhagen
- Price (as of 06/17/2026, 18:10 CET): 1,556.00 DKK
- Market cap: 102,000,000,000 DKK (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: OMX Copenhagen 25
- Next earnings date: 08/14/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
